Medications That Worsen Akathisia
Antipsychotic medications are the primary culprits that cause and worsen akathisia, with higher doses carrying greater risk, and increasing the dose of an antipsychotic in a patient with akathisia will exacerbate the condition rather than improve it.
Primary Offending Medications
Antipsychotics (Dose-Dependent Risk)
The risk of akathisia varies significantly among antipsychotics and increases with dose 1:
Highest Risk Antipsychotics:
- Cariprazine - highest akathisia incidence (17.2%), OR 4.35 vs placebo 2
- Lurasidone - 12.7% incidence, OR 3.74 vs placebo, with maximum risk at 240 mg/day 1, 2
- Aripiprazole - can cause severe akathisia even at low introductory doses 3
Moderate Risk:
- Brexpiprazole - 10.0% incidence, OR 2.04 vs placebo 2
- Asenapine - 6.8% incidence, OR 2.37 vs placebo 2
- High-potency conventional antipsychotics (haloperidol, fluphenazine) - historically associated with highest rates 4
Lower Risk:
- Iloperidone - 3.9% incidence, lowest among newer agents 2
- Quetiapine and sertindole - negligible risk across examined doses with flat dose-response curves 1
Antiemetics with Dopamine-Blocking Properties
Metoclopramide and prochlorperazine are well-documented causes of akathisia in general medical settings 5, 6. These medications possess central antidopaminergic effects and are frequently overlooked as akathisia triggers in non-psychiatric settings.
Other Medications
- Azithromycin - reported to cause akathisia in general medical settings 6
- SSRIs and other antidepressants - can precipitate akathisia, particularly when used as augmentation therapy 3
Critical Clinical Pitfall
The most dangerous error is increasing antipsychotic dosage when akathisia is mistaken for worsening psychosis or agitation 5. The subjective restlessness and objective motor symptoms of akathisia can be misinterpreted as psychiatric deterioration, leading clinicians to escalate the very medication causing the problem. This creates a vicious cycle of worsening symptoms.
Dose-Response Relationships
Most antipsychotics demonstrate either:
- Monotonic curves - risk continues rising with increasing doses
- Hyperbolic curves - risk increases initially then plateaus 1
Higher doses consistently carry greater or equal risk compared to lower doses 4. The average dose in patients with akathisia was 2294.5 mg chlorpromazine equivalents, with dose being the only factor significantly associated with akathisia after adjusting for confounders (p=0.01) 4.
Management Approach Per Guidelines
When akathisia occurs, the 2025 INTEGRATE guidelines 7 and 2020 APA guidelines 8 recommend:
- Dose reduction of the offending antipsychotic (if clinically feasible)
- Switch to lower-risk antipsychotic (quetiapine or olanzapine per 7)
- Adjunctive treatment:
The evidence best supports propranolol and mirtazapine as rescue agents 9, though the guidelines prioritize dose reduction and medication switching as first-line strategies.
Recognition Imperative
Akathisia remains largely underdiagnosed despite affecting 19.5% of patients on antipsychotics 4 and carrying severe psychiatric consequences including dysphoria (70%), anxiety (75%), suicidal thoughts (46%), and suicide attempts (38%) 4. The subjective component makes it particularly challenging to recognize, especially in general medical settings where it may be mistaken for anxiety 6.